Naval Daver

3.6k citations
148 papers · 1.6k · 1 hit paper · h-index 16

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 2%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 116
    • Acute Myeloid Leukemia Research 97
    • Chronic Myeloid Leukemia Treatments 42
    • Multiple Myeloma Research and Treatments 18
  • Genetics 57
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 32
    • Chronic Lymphocytic Leukemia Research 25
Co-authors
Farhad Ravandi (85 shared papers)Tapan M. Kadia (90 shared papers)Courtney D. DiNardo (74 shared papers)Marina Konopleva (40 shared papers)Nicholas J. Short (54 shared papers)Hagop M. Kantarjian (88 shared papers)Guillermo Garcia‐Manero (82 shared papers)Gautam Borthakur (46 shared papers)
Journals
Blood (82 papers)Journal of Clinical Oncology (28 papers)Cancer Research (4 papers)HemaSphere (4 papers)Haematologica (4 papers)
Partner nations
United StatesJapanChina

In The Last Decade

Naval Daver

130 papers receiving 1.6k citations

Naval Daver's Hit Papers

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges 2020 · 257 citations
2570+2+4Years since publication50100150200250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2020 Cancer Discovery

Peers

Naval Daver
Comparison fields: 5 of 76
  • Hematology 1.1k
  • Genetics 317
  • Public Health, Environmental and Occupational Health 486
  • Oncology 309
  • Molecular Biology 563
Replace Ulrike Schäkel with:
Ulrike Schäkel Germany
Christian Flotho Germany
Sanne Lugthart Netherlands
Anders Castor Sweden
S. Faderl United States
Tanja A. Grüber United States
Prashant Tembhare India
Deborah Thomas United States
Susana Vives Spain
Paulo Lúcio Portugal
Naval Daver relative to Ulrike Schäkel Germany Ulrike Schäkel's profile →
Citations per field
00.5×5×10×13.5×
Ulrike Schäkel · 1×
Citations per year

Countries citing papers authored by Naval Daver

Since Specialization
Citations

This map shows the geographic impact of Naval Daver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naval Daver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naval Daver more than expected).

Fields of papers citing papers by Naval Daver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naval Daver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naval Daver. The network helps show where Naval Daver may publish in the future.

Co-authors

The 25 scholars most cited alongside Naval Daver, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Naval Daver Line = papers co-authored together Naval Daver links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 148 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Cancer Discovery ·Nicholas J. Short, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo, Naval Daver
Hit paper breakdown →		2020257
2
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
The Lancet Haematology ·Elias Jabbour, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Koji Sasaki, Jörge E. Cortes, Rebecca Garris, Joseph D. Khoury, Jeffrey L. Jorgensen, Nitin Jain, Joie Alvarez, Susan O’Brien, Hagop M. Kantarjian
2018163
3
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis
Cancer ·Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Marina Konopleva, Nitin Jain, Ghayas C. Issa, Vicki Jeanis, Haim G. Moore, Rebecca Garris, Naveen Pemmaraju, Jörge E. Cortes, Susan O’Brien, Hagop M. Kantarjian
2016139
4
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Clinical Lymphoma Myeloma & Leukemia ·Rita Assi, Hagop M. Kantarjian, Nicholas J. Short, Naval Daver, Koichi Takahashi, Guillermo Garcia‐Manero, Courtney D. DiNardo, Jan A. Burger, Jörge E. Cortes, Nitin Jain, William G. Wierda, S Chamoun, Marina Konopleva, Elias Jabbour
2017120
5
Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia
American Journal of Hematology ·Maro Ohanian, Guillermo Garcia‐Manero, Mark J. Levis, Elias Jabbour, Naval Daver, Gautam Borthakur, Tapan M. Kadia, Sherry Pierce, Jan A. Burger, Mary Ann Richie, Keyur P. Patel, Michael Andreeff, Zeev Estrov, Jörge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi
201895
6
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
Cancer ·Farhad Ravandi, Jeffrey L. Jorgensen, Gautam Borthakur, Elias Jabbour, Tapan M. Kadia, Sherry Pierce, Mark Brandt, Sa Wang, Sergej Konoplev, Xuemei Wang, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Michael Andreeff, Marina Konopleva, Zeev Estrov, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian
201658
7
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
Blood ·Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver, Gautam Borthakur, Maro Ohanian, Tapan M. Kadia, Courtney D. DiNardo, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia‐Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Elias Jabbour, William G. Wierda, Farhad Ravandi, Maria Rhona Pinsoy, Jörge E. Cortes
201758
8
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia
Leukemia ·Mansour Alfayez, Ghayas C. Issa, Keyur P. Patel, Feng Wang, Xuemei Wang, Nicholas J. Short, Jörge E. Cortes, Tapan M. Kadia, Farhad Ravandi, Sherry Pierce, Rita Assi, Guillermo Garcia‐Manero, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Hagop M. Kantarjian, Gautam Borthakur
202045
9
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Haematologica ·Yannan Jia, Lina Han, Cassandra L. Ramage, Zhe Wang, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva
202339
10
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
Journal of Clinical Oncology ·Naval Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel N. Mannis, Wanxing Chai‐Ho, Tiffany Tanaka, Terrence Bradley, Deepa Jeyakumar, Eunice S. Wang, Guan Xing, Mark P. Chao, Giridharan Ramsingh, Camille Renard, Indu Lal, Joshua F. Zeidner, David A. Sallman
202238
11
A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy
Blood ·Guillermo Garcia‐Manero, Elias Jabbour, Marina Konopleva, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Prithviraj Bose, Parita Patel, Rami S. Komrokji, Aditi Shastri, Gail J. Roboz, Robert M. Miller, Sarah Arbe‐Barnes, Mary M. Reilly, Peter McGuirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian
201832
12
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
American Journal of Hematology ·Aziz Nazha, Hagop M. Kantarjian, Farhad Ravandi, Xuelin Huang, Sangbum Choi, Guillermo Garcia‐Manero, Elias Jabbour, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Jörge E. Cortes, Alessandra Ferrajoli, Steve Kornblau, Naval Daver, Naveen Pemmaraju, Michael Andreeff, Zeev Estrov, Min Du, Mark Brandt, Stefan Faderl
201332
13
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia
British Journal of Haematology ·Sanam Loghavi, Courtney D. DiNardo, Ken Furudate, Koichi Takahashi, Tomoyuki Tanaka, Nicholas J. Short, Tapan M. Kadia, Marina Konopleva, Rashmi Kanagal‐Shamanna, Noushin Farnoud, Sherry Pierce, Joseph D. Khoury, Jeffrey L. Jorgensen, Keyur P. Patel, Naval Daver, Musa Yılmaz, L. Jeffrey Medeiros, Hagop M. Kantarjian, Farhad Ravandi, Sa A. Wang
202127
14
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML
Blood ·Maro Ohanian, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Guillermo Garcia‐Manero, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Elias Jabbour, Naval Daver, Steven M. Kornblau, William G. Wierda, Jan A. Burger, Kiran Naqvi, Christopher B. Benton, Prithviraj Bose, John R. Eckardt, Farhad Ravandi, Jörge E. Cortes
201622
15
Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial
Blood ·Musa Yılmaz, Hagop M. Kantarjian, Muharrem Müftüoğlu, Tapan M. Kadia, Marina Konopleva, Gautam Borthakur, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Yesid Alvarado, Guillermo Montalban‐Bravo, Carissa Jurisprudencia, Allison Pike, Maro Ohanian, Elias Jabbour, Guillermo Garcia‐Manero, Vivian Ruvolo, Farhad Ravandi, Michael Andreeff, Naval Daver
202019
16
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
Journal of Clinical Oncology ·David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver
202216
17
Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results
Blood ·Prithviraj Bose, Srđan Verstovšek, Yvonne Gasior, Nitin Jain, Elias Jabbour, Zeev Estrov, Yesid Alvarado, Courtney D. DiNardo, Naveen Pemmaraju, Steven M. Kornblau, Tapan M. Kadia, Naval Daver, Mark Brandt, Sherry Pierce, Graciela M. Nogueras‐González, Xuelin Huang, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Farhad Ravandi
201615
18
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
Haematologica ·Samer A. Srour, Amanda Olson, Stefan O. Ciurea, Parth Desai, Qaiser Bashir, Betül Oran, Prithviraj Bose, Rohtesh S. Mehta, Keyur P. Patel, Naveen Pemmaraju, Naval Daver, Srđan Verstovšek, Richard E. Champlin, Uday Popat
201915
19
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
Blood ·Waleed Abdelall, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia‐Manero, Keyur P. Patel, Elias Jabbour, Naval Daver, Tapan M. Kadia, Rosilyn A. Gborogen, Marina Konopleva, Farhad Ravandi, Michael Andreef, Jörge E. Cortes
201614
20
Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
Blood ·Preetesh Jain, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Naval Daver, Naveen Pemmaraju, Courtney D. DiNardo, Yesid Alvarado, Nitin Jain, Gautam Borthakur, Srđan Verstovšek, Alessandra Ferrajoli, Maro Ohanian, Marina Konopleva, Kiran Naqvi, Tina Fitch, Guillermo Garcia‐Manero, Jörge E. Cortes, Zeev Estrov, Tapan M. Kadia
201613

About Naval Daver

Naval Daver is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Oncology, having authored 148 papers that have together received 1.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (97 papers), Chronic Myeloid Leukemia Treatments (42 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Acute Lymphoblastic Leukemia research (29 papers), Chronic Lymphocytic Leukemia Research (25 papers), Protein Degradation and Inhibitors (22 papers), Multiple Myeloma Research and Treatments (18 papers) and CAR-T cell therapy research (14 papers). The work is most often cited by research in Hematology (1.1k citations), Genetics (317 citations), Public Health, Environmental and Occupational Health (486 citations), Oncology (309 citations) and Molecular Biology (563 citations). Naval Daver has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Nicholas J. Short, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam Borthakur, Jörge E. Cortes and Elias Jabbour. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, HemaSphere and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrike SchäkelBreakdown of academic impact, for papers by Christian FlothoBreakdown of academic impact, for papers by Sanne LugthartBreakdown of academic impact, for papers by Anders CastorBreakdown of academic impact, for papers by S. FaderlBreakdown of academic impact, for papers by Tanja A. GrüberBreakdown of academic impact, for papers by Prashant TembhareBreakdown of academic impact, for papers by Deborah ThomasBreakdown of academic impact, for papers by Susana VivesBreakdown of academic impact, for papers by Paulo Lúcio